Enhance your understanding of MET biomarkers in NSCLC

HGF/MET pathway dysregulation can contribute to NSCLC by enhancing cancer cell proliferation, survival, and invasion.1

HGF=hepatocyte growth factor; NSCLC=non-small cell lung cancer.

MET in NSCLC

Discover more about MET biomarkers in NSCLC, including detection methods and biomarker overlap.

Discover

Case Atlas

Explore a collection of NSCLC cases with a range of c-Met protein staining patterns.

Explore

Self-Assessment

Practice your assessment with NSCLC cases that span c-Met protein expression.

Practice

Resource Library

Download free website resources to take with you.

Download
NSCLC=non-small cell lung cancer.
Reference
  1. Liang H, Wang M. Onco Targets Ther. 2020;13:2491-2510. doi:10.2147/OTT.S231257.
Developed and authored by AbbVie US Medical Affairs.
© 2026 AbbVie Inc. All rights reserved.
ABBV-US-02050-MC, v2.0
Approved: May 2026
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Accessibility Statement Medical Information Terms of Use Contact Us Privacy Notice
Cookies Settings
Your Privacy Choices
Welcome to DISCOVER MET

This website is for healthcare professionals inside the United States only and is provided for informational purposes only.

Are you a healthcare professional practicing in the United States?

Yes, I am a healthcare professional in the US
No, take me to AbbVie.com